Law360, New York (September 8, 2011, 6:33 PM EDT) -- A Pennsylvania federal judge on Thursday approved the dismissal of health insurer AvMed Inc.'s antitrust claims from consolidated class action litigation against Cephalon Inc. and generics makers over an alleged conspiracy to keep narcolepsy drug Provigil off the market.
AvMed's claims were consolidated with class actions filed over the alleged conspiracy by drug plans, wholesalers and Apotex Inc., who say they were left out of Cephalon's alleged scheme of payoffs to other generic-drug makers. This marks the first dismissal in the case.
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.